Abstract
Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have